Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: Nov 9, 2023

Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio

SPY001, a half-life extended anti-α4β7 antibody, is on track for an expected IND filing in the first half of 2024, with interim healthy volunteer, proof of concept pharmacokinetic data expected year-end 2024